nct_id,title,has_us_facility,conditions,eligibility_criteria
NCT00484263,The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  diagnosis of bronchiectasis on high resolution computer tomography

          -  at least 2 respiratory exacerbations per year over the past 2 years

          -  producing sputum daily

          -  in a stable clinical state

          -  over 18 years of age.

        Exclusion Criteria:

          -  cystic fibrosis

          -  Positive response to hypertonic saline challenge - FEV 1 decreased by ≥ 15%

          -  FEV 1 ≤ 1L
"
NCT00728715,Efficacy of Budesonide-Formoterol in Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  18-80 years old patients diagnosed of non-cystic fibrosis bronchiectasis

          -  More than 1 pulmonary lobe affected

          -  Chronic obstructive airflow obstruction

          -  Stable phase of the disease

        Exclusion Criteria:

          -  Asthma, COPD or current/past smnokers

          -  No consent

          -  Known intolerance to budesonide or formoterol
"
NCT00749866,Long Term Nebulised Gentamicin in Patients With Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Bronchiectasis confirmed by HRCT of the chest

          -  Clinically stable (not requiring antibiotics for at least 4 weeks preceding the study
             start date)

          -  Aged 18-70

          -  Chronic sputum production > 5 mls for the majority of days in 3 months before
             enrolment

          -  Chronically colonized (on at least 2 occasions in the preceding 12 months) whilst
             clinically stable

          -  At least two exacerbations in the past year

          -  Patients able to tolerate a nebulized gentamicin challenge

          -  FEV1 > 30% predicted

          -  Smoking < 20 pack year history and ex-smokers >1 year.

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Emphysema on HRCT chest

          -  Thoracic surgery within the past 1 year

          -  Allergic bronchopulmonary aspergillosis

          -  Poorly controlled asthma ( > 20% diurnal variation in peak expiratory flows despite
             treatment)

          -  Unstable angina or uncontrolled congestive cardiac failure

          -  Active malignancy

          -  Pregnancy or breast feeding

          -  Creatinine clearance < 30 mls/minute

          -  Vestibular instability

          -  Previous documented intolerance to aminoglycosides
"
NCT00816309,"Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Moderate and Severe Bronchiectasis

          -  No regular chest physiotherapy

        Exclusion Criteria:

          -  Moderate or Severe COPD
"
NCT00868075,Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients with moderate and severe bronchiectasis aged 18-75 will be recruited.
             Severity will be assessed radiologically by HRCT of the chest using the scoring method
             by Bhalla et al.

        Exclusion Criteria:

          -  cystic fibrosis

          -  emphysema on HRCT chest and FEV1<60% predicted

          -  active allergic bronchopulmonary aspergillosis or tuberculosis

          -  poorly controlled asthma

          -  pregnancy or breast feeding

          -  current smokers
"
NCT00885521,Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Diagnosis of bronchiectasis (HRCT)

          -  Stable medical status for last 4 weeks

          -  History of 2 exacerbations in the last 2 years

          -  Dysnpoea on exertion (Modified Medical Research Council score >1)

        Exclusion Criteria:

          -  Concurrent diagnosis of COPD (physician diagnosis and history of 10 pack year smoking)

          -  Concurrent diagnosis of asthma (history of atopic disease and evidence of
             bronchodilator reversibility of 12% or 200ml in FEV1 or FVC)

          -  Concurrent diagnosis of Interstitial lung disease

          -  Concurrent diagnosis of Cystic Fibrosis

          -  Medical condition which could place patient at risk during exercise training (angina,
             neurological or orthopaedic condition)

          -  Prior completion of pulmonary rehabilitation within the last 12 months
"
NCT00889967,"Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis ""ORBIT-1""",TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Are willing and able to provide written informed consent.

          2. Are males or females 18 to 80 year of age, inclusive.

          3. Have had a confirmed diagnosis of non-CF bronchiectasis per high resolution computed
             tomography (HRCT) for at least 4 years.

          4. Confirmation of infection with P. aeruginosa at screening

        Exclusion Criteria:

          1. Have a known local or systemic hypersensitivity to fluoroquinolone or quinolone
             antibiotics.

          2. Have an exacerbation during the Screening Phase as defined as requiring treatment with
             inhaled, oral, or intravenous antibiotics prior to the first dose of study drug.

          3. Have a diagnosis of cystic fibrosis..

          4. Have had changes in either the treatment regimen or initiation of treatment with any
             of the following medications within 28 days prior to Visit 1:

               -  Azithromycin

               -  Hypertonic saline

               -  Bronchodilator medications

               -  Oral corticosteroid.

          5. Have received an investigational drug or device within 28 days prior to Visit 1.

          6. Have any serious or active medical or psychiatric illness, which in the opinion of the
             investigator, would interfere with patients' treatment, assessment, or compliance with
             the protocol.
"
NCT00930982,Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or
             post pneumonic bronchiectasis

          -  Stable pulmonary status and stable regimen of standard treatment at least for the past
             30 days

        Exclusion Criteria:

          -  Forced Expiratory Volume 1 < 35% or > 80%

          -  Allergic bronchopulmonary aspergillosis

          -  Immunodeficiency disease requiring immunoglobulin replacement

          -  Inflammatory bowel disease
"
NCT01299181,A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients aged 18-75 will be recruited. All will have an established radiological
             diagnosis of bronchiectasis (CT of the chest). Patients will have clinically
             significant bronchiectasis expectorating mucopurulent or purulent sputum when
             clinically stable with at least 2 chest infections per year.

        Exclusion Criteria:

          -  current smokers or ex-smokers of less than 1 year; >15 pack year history

          -  cystic fibrosis

          -  active allergic bronchopulmonary aspergillosis

          -  active tuberculosis

          -  poorly controlled asthma

          -  pregnancy or breast feeding

          -  known allergy to statins

          -  active malignancy

          -  chronic liver disease

          -  established cardiovascular or cerebrovascular disease

          -  statin use in the last year

          -  patients on long term oral macrolides due to the interaction with statin therapy
             patients chronically colonised with Pseudomonas aeruginosa (defined as two or more
             isolates of Pseudomonas aeruginosa whilst clinically stable in 6 months prior to the
             study).
"
NCT01299194,Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients aged 18-80 will be recruited.

          -  All will have an established radiological diagnosis of bronchiectasis (CT of the
             chest).

          -  Patients colonised with Pseudomonas Aeruginosa.

          -  Able to give informed consent.

        Exclusion Criteria:

          -  Current smokers or ex-smokers of less than 1 year; >15 pack year history

          -  Cystic fibrosis

          -  Active allergic bronchopulmonary aspergillosis

          -  Active tuberculosis

          -  Poorly controlled asthma

          -  Pregnancy or breast feeding

          -  Known allergy to statins

          -  Active malignancy

          -  Chronic liver disease

          -  Established cardiovascular or cerebrovascular disease

          -  Statin use in the last year
"
NCT01313624,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male/Female 18 years or older with non-CF bronchiectasis

          -  Chronic sputum production on most days

          -  Positive sputum culture for gram-negative organisms

          -  Must have met lung function requirements

        Exclusion Criteria:

          -  History of CF

          -  Hospitalized within 14 days prior to joining the study

          -  Previous exposure to AZLI

          -  Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study

          -  Must have met liver and kidney function requirements

          -  Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with
             activity and at night was allowed)

          -  Treatment for nontuberculous mycobacteria infection or active mycobacterium
             tuberculosis infection within 1 year of enrollment

          -  Other serious medical conditions.
"
NCT01314716,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male/Female 18 years or older with non-CF bronchiectasis

          -  Chronic sputum production on most days

          -  Positive sputum culture for gram-negative organisms

          -  Must have met lung function requirements

        Exclusion Criteria:

          -  History of CF

          -  Hospitalized within 14 days prior to joining the study

          -  Previous exposure to AZLI

          -  Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study

          -  Must have met liver and kidney function requirements

          -  Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with
             activity and at night was allowed)

          -  Treatment for nontuberculous mycobacteria infection or active mycobacterium
             tuberculosis infection within 1 year of enrollment

          -  Other serious medical conditions.
"
NCT01463371,Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Previous diagnosis of bronchiectasis based on lung HRCT and clinical symptoms

          -  Clinically stable in previous four weeks without exacerbations

          -  Informed consent

        Exclusion Criteria:

          -  Bronchiectasis secondary to Cystic fibrosis, pulmonary surgical processes, immune
             deficiency, emphysema, allergic bronchopulmonary aspergillosis or diffuse interstitial
             pulmonary diseases

          -  Intolerance to macrolides or severe liver disease.
"
NCT01515007,Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3),TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Verified bronchiectasis diagnosis

          -  Pseudomonas aeruginosa lung infection

        Exclusion Criteria:

          -  Cystic Fibrosis
"
NCT01684683,The Effect of Theophylline in the Treatment of Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients between 18-70 years old with non-CF bronchiectasis ,free from acute
             exacerbations for at least 3 months.Stable phase of the disease.

        Exclusion Criteria:

          -  Patients with a cigarette smoking history of more than 10 packs-year. Patients with
             COPD. Patients with traction bronchiectasis due to advanced fibrosis. Patients with
             known intolerance for theophylline. Patients with asthma. Patients with other disease
             disturbing outcomes of the trials. Patients without consent.
"
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic
             or post infectious bronchiectasis

          -  Stable pulmonary status and stable regimen of standard treatment at least for the past
             4 weeks

        Exclusion Criteria:

          -  Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted

          -  Active allergic bronchopulmonary aspergillosis

          -  Active and actively treated non tuberculosis mycobacterial (NTM) infection or
             tuberculosis

          -  Primary diagnosis of Chronic obstructive pulmonary disease (COPD)
"
NCT01792427,Mortality in Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients with clinically significant and radiologically proven bronchiectasis

          -  Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of
             chronic productive cough

          -  Bronchiectasis was deemed to be present if there was one or more of the following
             criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and
             visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the
             mediastinal pleura

        Exclusion Criteria:

          -  diagnosis of cystic fibrosis

          -  underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy,
             secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral
             obstruction)

          -  patients with asymptomatic traction bronchiectasis caused by interstitial lung disease
"
NCT01792440,The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Diagnosis of NCFB, based on CT findings of bronchiectatic disease in the absence of
             cystic fibrosis (CF) as a cause.

          -  stable

        Exclusion Criteria:

          -  no recent exacerbation
"
NCT01801657,The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  HRCT-diagnosed Bronchiectasis

          -  Capable of providing written informed consent

        Exclusion Criteria:

          -  Patient judged to have poor compliance

          -  Cystic fibrosis bronchiectasis
"
NCT01818544,Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Proven and documented diagnosis of non-CF (cystic fibrosis) idiopathic or
             post-infectious BE (bronchiectasis) by computed tomography (CT) scan [conventional
             high resolution CT is considered the standard], including 2 or more lobes and dilated
             airways compatible with BE at initial diagnosis

          -  Stable pulmonary status as indicated by the forced, expired volume in 1 second (FEV1)
             percent predicted ≥30% and <90% (post-bronchodilator)

          -  Stable (i.e., no dose change) regimen of standard BE treatment administered at least
             for 4 weeks prior to screening

          -  Cough on most days

        Exclusion Criteria:

          -  Forced, expired volume in 1 second <30% or ≥90% predicted (post-bronchodilator)

          -  Recent significant hemoptysis (≥300 mL or requiring blood transfusion) in the
             preceding 4 weeks before screening (and during the screening period)

          -  Known cystic fibrosis and/or documented chronic bronchial asthma

          -  Active allergic bronchopulmonary aspergillosis (ABPA)

          -  Diagnosis of common variable immunodeficiency (CVID)

          -  Systemic or inhaled antibiotic treatment within 4 weeks prior to screening

          -  Treatment of an exacerbation within 4 weeks prior to screening

          -  Systemic corticosteroids at >10 mg/day prednisolone equivalent for >2 weeks within 4
             weeks prior to screening
"
NCT01854788,3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. - Non Cystic Fibrosis bronchiectasis diagnosed by High Resolution Computed Tomographic

          2. - Mean sputum production ≥ 15 ml /24h

          3. - Clinical stability in the last 6 weeks

          4. - Not carrying out regular chest physiotherapy

          5. - Forced expiratory volume in 1 second ≥ 30% pred. ; Forced Vital Capacity ≥ 45% pred.
             and peak expiratory flow >270 L/s

        Exclusion Criteria:

          1. - Smoker or non-smoker form less than 2 years

          2. - Cystic fibrosis

          3. - Active tuberculosis or sarcoidosis
"
NCT01906047,Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  HRCT diagnosis of bronchiectasis

          -  recurrent infections or chronic sputum production

          -  patients between 18 and 65 years old.

        Exclusion Criteria:

          -  Cystic Fibrosis

          -  Tumoral disease

          -  Traction bronchiectasis due to interstitial lung disease

          -  patients older than 65 years or younger than 18 years at recruitment

          -  COPD
"
NCT02035488,Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion criteria:

          -  Age 18 years or older

          -  Obtained informed consent

          -  Patients having bronchiectasis (confirmed with HR-CT of the chest)

        Exclusion criteria:

          -  Pregnant or breast feeding

          -  Subjects with known or suspected renal, auditory, vestibular or neuromuscular
             dysfunction, or with severe, active haemoptysis,

          -  History of adverse events on previous tobramycin or other aminoglycoside use

          -  No concurrent use of cyclosporin, cisplatin, amfotericin B, cephalosporins,
             polymyxins, vancomycin and NSAIDs.
"
NCT02081963,Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male or female study subjects ≥18 years of age and ≤80 years of age;

          -  Confirmed diagnosis of idiopathic bronchiectasis or postinfectious bronchiectasis;

          -  Confirmation of infection with Pseudomonas aeruginosa at screening;

          -  Are sensitive to amikacin;

          -  Acute exacerbation of bronchiectasis.

        Exclusion Criteria:

          -  Bronchiectasis due to special causes;

          -  Smokers;

          -  Are associated with bronchial asthma;

          -  Have any serious or active medical or psychiatric illness;

          -  Be allergic to amikacin or not tolerant to nebulised amikacin(FEV1 reduces ≥15% after
             inhaling amikacin.
"
NCT02088216,"Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. subjects were aged 18-80 years old;

          2. a diagnosis of idiopathic or post-infective bronchiectasis was made;

          3. patients had at least two exacerbations in the past year and were in a stable state
             for at least 4 weeks prior to the primary enrollment.

        Exclusion Criteria:

        Patients were excluded if they fulfilled any of the following criteria: current smokers;
        cigarette smoking within 6 months; cystic fibrosis or other etiologies (such as
        immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused
        by emphysema, advanced pulmonary fibrosis, etc.); pulmonary function test results showing a
        forced expiratory volume in 1 s (FEV1) ≤ 30% of the predicted value; a history of severe
        cardiovascular or neurological disease; comorbidity with liver disease, kidney disease,
        malignant tumor, gastric ulcer, or intestinal malabsorption; a known allergy to
        N-acetylcysteine; pregnancy or lactation (for women); a history of prior macrolide use of
        more than 1 week; and poor compliance.
"
NCT02096315,"Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Male and female aged ≥18 to <80 years and suffering from exacerbation of non-cystic
             fibrosis bronchiectasis due to Pseudomonas aeruginosa infection

          2. Sputum sample collected for culture before starting treatment

        Exclusion Criteria:

          1. Female patients who are pregnant or breast feeding or unwilling to follow reliable
             method of contraception

          2. Subjects suffering from cystic fibrosis, active pulmonary mycobacterial infection, end
             stage chronic obstructive pulmonary disease on long term oxygen therapy, severe
             uncontrolled asthma, active sarcoidosis and active allergic broncho-pulmonary
             aspergillosis

          3. Current exacerbation of bronchiectasis is associated with lung abscess or empyema

          4. Current exacerbation episode is suspected or documented to be due to pathogens other
             than Pseudomonas aeruginosa

          5. Patients with known HIV infection with CD4+ (cluster of differentiation 4) cell count
             < 200/mm3

          6. Patients who are currently enrolled in, or have not yet completed at least 30 days
             since ending another investigational device or drug trial or are receiving other
             investigational agent
"
NCT02104245,Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4),TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Confirmed diagnosis of non-CF bronchiectasis

          -  History of P. aeruginosa respiratory infections

          -  At least two pulmonary exacerbations treated with antibiotics in the previous year

        Exclusion Criteria:

          -  Have a clinical diagnosis of CF

          -  Are pregnant
"
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients with a proven and documented diagnosis of non CF idiopathic or post
             infectious bronchiectasis

          -  Stable pulmonary status and stable regimen of standard treatment at least for the past
             4 weeks

        Exclusion Criteria:

          -  Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted

          -  Active allergic bronchopulmonary aspergillosis

          -  Active and actively treated non tuberculosis mycobacterial (NTM) infection or
             tuberculosis

          -  Primary diagnosis of Chronic obstructive pulmonary disease (COPD)
"
NCT02163642,Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Diagnosis of non- CF bronchiectasis based on at least 1 lobe with bronchial dilatation
             and compatible clinical symptoms such as cough, sputum production and respiratory
             infections.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Presence of exacerbation in the last 4 weeks.

          -  Antibiotic treatment in the last 4 weeks

          -  Use of oral corticosteroids in the last 4 weeks

          -  Concomitant terminal illness.

          -  Current cigarette smoking

          -  Active allergic bronchopulmonary aspergillosis

          -  Diagnosis of tuberculosis or active non-tuberculous Mycobacterial infection
"
NCT02324855,Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Chronic sputum production during at least 3 months previous enrolment

          -  At least two confirmed exacerbations during the last year

          -  Patients able to understand how to perform the airway clearance techniques

          -  Clinically stable at time of study entry (defined as no requirement for antibiotics or
             change in respiratory medication in the preceding 4 wk)

          -  To be able to provide written, informed consent

        Exclusion Criteria:

          -  Cystic Fibrosis

          -  Carry out regular chest physiotherapy.

          -  Active haemoptysis during the previous month or recurrent hemoptysis during the last
             year (more than 4 episodes)

          -  Waiting a pulmonary transplant
"
NCT02392663,Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Non-cystic Fibrosis bronchiectasis (NCFBE) diagnosed by High Resolution Computed
             Tomographic

          2. Mean sputum production ≥ 10 ml /24h.

          3. Clinical stability in the last 4 weeks

          4. To be able to understand how to perform inhalation and the physiotherapy session.

          5. To be able to provide written, informed consent

        Exclusion Criteria:

          1. Forced expiratory volume in 1 second < 30% pred. ; Total lung capacity < 45% pred.

          2. Performing nebulization with any hyperosmolar agents, previously

          3. Allergic bronchopulmonary aspergillosis diagnosis

          4. Not to be able to overcome the safety test pre-intervention (oxygen saturation levels
             drop to < 90% and/or forced expiratory volume in 1 second decline more than < 12% from
             baseline during the nebulization process)
"
NCT02411981,Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Non cystic fibrosis bronchiectasis in stable state

        Exclusion Criteria:

          -  Not in stable state

          -  Bronchiectasis with severe respiratory morbidities likely to reduce the chest
             physiotherapy session efficacy (e.g. : severe chronic obstructive pulmonary disease)
"
NCT02507843,Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Diagnosis of non-Cystic fibrosis bronchiectasis by High Resolution CT

          -  Age 18 years or older

          -  Vitamin D deficiency [25(OH)D<20 ng/mL]

          -  Informed consent

        Exclusion Criteria:

          -  Current active allergic bronchopulmonary or tuberculosis

          -  Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis,
             pulmonary silicosis, Human Immunodeficiency Virus infection, liver failure, renal
             failure or malignancy

          -  Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital,
             phenytoin or primidone

          -  Taking dietary supplement or topical preparation containing vitamin D up to 2 months
             before first dose

          -  Treatment with any investigational medical product or device up to 4 months before
             first dose

          -  Breastfeeding, pregnant or planning a pregnancy

          -  Baseline corrected serum calcium > 2.65 mmol/L

          -  Baseline serum creatinine > 125 micromol/L
"
NCT02531984,The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Presenting with non cystic fibrosis bronchiectasis documented by chest CT scan ,
             diagnosed since at least 2 years

          -  Already treated with azithromycin for at least 6 months

          -  Presented no respiratory exacerbation since one month

          -  Benefit from health insurance

          -  Have signed a consent (if appropriate age )

          -  Parents or legal guardian have given their written consent

        Exclusion Criteria:

          -  Patients presenting a history of allergic reaction to azithromycin, érythromycine,
             another macrolide or Ketolide or an excipient of Zithromax

          -  Patients treated with dihydroergotamine or ergotamine , cisapride, colchicine

          -  Patients presenting severe hepatic failure

          -  Patients who are unlikely to adhere to the protocol and hence participate in the
             entire study ( as judged by the investigator )

          -  Patients who have not signed the protocol

          -  Patients whose parents are unable to understand the purpose and conditions of the
             study or are unable to give their consent.

          -  Patients already included in another clinical trial or are in an exclusion period from
             a previous clinical trial

          -  Patients whose ECG shows a QTc > 450 msec ( Zithromax is contraindicated )
"
NCT02563197,Inhalation Flow Rate-study,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented
             by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)

          -  Ability to reproducibly perform spirometry according to American Thoracic
             Society/European Respiratory Society criteria

          -  Clinically stable in the opinion of the investigator at the time of the study visit.

          -  Male and female patients ≥ 18 years of age.

        Exclusion Criteria:

          -  Pulmonary exacerbation (as judged by the investigator, based on the clinical condition
             of the subject and taking into account e.g., febrile infection of the lung, relevant
             decrease in Forced expiratory volume in the first second (FEV1) value, increased
             sputum production, sputum purulence, recent hospitalization) at study visit or within
             the preceding six (6) weeks.

          -  History of lung transplant.

          -  Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the
             preceding six (6) weeks before screening.

          -  Established diagnosis of bronchial asthma.

          -  Established diagnosis of cystic fibrosis.

          -  Proof of any relevant medical finding or disease in the last three (3) months which
             might interfere with participation in the study or patient safety (e.g. pneumothorax,
             uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction,
             cerebral vascular accident).

          -  A relevant disease that is considered to interfere with the study results is any
             disease that, except for the impairment of lung function, interferes with the
             patient's ability to inhale from the device. For example, COPD per se is usually not
             considered as a reason for patient exclusion, unless coughing or obliteration of the
             upper airways with sputum interferes with the patient's ability to inhale from the
             device.

          -  Relevant surgical history in the last 3 months (e.g., but not limited to abdominal,
             thoracic, ocular or brain surgery).

          -  History or evidence of lung resection, thoracotomy, known aneurysm and severe
             scoliosis.

          -  Pregnancy.
"
NCT02614300,The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Aged between 50-80 years;

          -  No performing regular physiotherapy treatment or physical training (≤ 1 time/week);

          -  Stable disease [no changes in the chronic therapy (both inhaled and systematic) in the
             usual respiratory symptoms (according to the medical evaluation) and spirometry in the
             last 4 weeks prior to study recruitment];

          -  Regular cough and expectoration;

          -  Ability to follow the exercise program;

          -  Ability to perform all clinical tests, to understand the process and the purposes of
             the study;

          -  A history of at least 2 exacerbations during the previous year requiring antibiotic
             treatment and;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Active smokers, ex-smokers of less than 1 year prior to recruitment and/or a history
             of >20 smoking packs/year;

          -  FEV1 <30% or/and TLC<40% ;

          -  Diagnosis of cystic fibrosis, sarcoidosis, pulmonary fibrosis, active tuberculosis or
             non tuberculosis mycobacterial infection,

          -  Diagnosis of asthma or COPD as a primary respiratory disease and associated secondary
             bronchiectasis,

          -  Patients with unstable cardiac disease or locomotor difficulties that preclude
             exercise (eg, severe arthritis or severe peripheral vascular disease);

          -  Chronic respiratory failure and/or oxygen therapy;

          -  Frequent haemoptysis (≥ 2 times/month);

          -  Participation in a PR program during the year prior to inclusion or during the study
             protocol;

          -  Participation in a CP program during 1 month prior to inclusion;

          -  Any physical and psychological disorder that interferes with protocol compliance;

          -  Participation in a clinical trial implying any change in usual pharmacological
             treatment in the last 6 months before recruitment;

          -  Being on the waiting list for lung transplantation or have been transplanted.
"
NCT02625246,Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Provide written informed consent,

          -  be between 30 and 87 years old at the time of signing the Informed Consent,

          -  weight over 45 and under 150 kg,

          -  have a clinical diagnosis of non-CF bronchiectasis prior to screening,

          -  Have had at least 2 exacerbations in the past year as documented by physician office
             or hospital visits (Use of antibiotics of at least one time in the last year),

          -  Show a baseline FEV1 between 25% and 85% predicted and over or equal to 1 L and a
             baseline diffusion capacity of lung for carbon monoxide (DLCO) over or equal to 30%
             (corrected for hemoglobin but not alveolar volume),

          -  Have a normal Right Ventricular function, as documented by Doppler echo or right heart
             catheterization,

          -  if a female of childbearing potential, agree to abide by contraception rules defined
             below.

          -  Subjects may receive nondrug therapies including oxygen supplementation not greater
             than 4 Liters per minute and pulmonary rehabilitation.

          -  Subjects may be on chronic macrolide or inhaled antibiotic treatment bronchiectasis

        Exclusion Criteria:

          -  Have HRCT and or surgical lung biopsy results inconsistent with the diagnosis of
             non-CF bronchiectasis. (Exclusion of emphysema and or diffuse parenchymal disease)

          -  be unable to perform any of the assessments required for endpoint analysis (report
             safety or tolerability concerns, perform Pulmonary Function Tests (PFT) or HRCT,
             undergo blood draws, read and respond to questionnaire

          -  If a female of childbearing potential, have a follicle stimulating hormone (FSH) under
             25.8 IU/L

          -  be actively treated for an acute infectious exacerbation of bronchiectasis

          -  Have an active infection that is not treated

          -  Have had active infections occurring within a minimum of 4 weeks of study treatment

          -  Be currently on treatment for NTM infections

          -  Have had positive sputum cultures for nontuberculous mycobacterial (NTM) within the
             past 6 months

          -  Have a history of drug or alcohol abuse within the past 24 months.

          -  Be currently receiving (or have received within four weeks of screening) experimental
             agents for the treatment of bronchiectasis or have been enrolled in clinical trials
             within the previous 30 days

          -  Be actively listed (or expect future listing) for transplant of any organ.

          -  Have clinically important abnormal screening laboratory values.

          -  Have a serious comorbid illness that, in the opinion of the investigator, may
             compromise the safety or compliance of the patient or preclude successful completion
             of the study.

          -  Have any other condition that, in the opinion of the investigator, may compromise the
             safety or compliance of the patient or preclude successful completion of the study.

          -  Have known allergies to penicillin or streptomycin.

          -  Be an organ transplant recipient.

          -  Have a clinical history of malignancy within 5 years (i.e., patients with prior
             malignancy must be disease free for 5 years), except curatively-treated basal cell
             carcinoma of skin, squamous cell carcinoma of skin, or cervical carcinoma.

          -  Have a non-pulmonary condition that limits lifespan to less than 1 year.

          -  Be serum positive for HIV, hepatitis BsAg (surface agent reactive) or Viremic
             hepatitis C.

          -  Have hypersensitivity to dimethyl sulfoxide (DMSO)

          -  Be unable to maintain saturated oxygen (SpO2) of more than 93% on room air at sea
             level at rest) or an SpO2 of more than 88% on room air over 5,000 feet (1524 meters)
             above sea level at rest.
"
NCT02657473,Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of
             sputum

          3. Confirmed non-CF bronchiectasis by (HR)CT

          4. Documented history of at least 2 pulmonary exacerbations treated with courses of
             antibiotics within 12 months before inclusion.

          5. No course of antibiotics or maintenance antibiotics (except for macrolides) 1 month
             prior to the start of the study.

          6. Minimal one documented sputum or BAL-fluid culture with gram-negative bacteria or
             S.aureus within 12 months.

          7. Growth of protocol defined pathogens in sputum at screening visit sensitive to
             tobramycin

          8. Tolerance of inhaled tobramycin

        Exclusion Criteria:

          1. Any exacerbation within the month prior to the start of the study

          2. Diagnosis of cystic fibrosis

          3. Active allergic bronchopulmonary aspergillosis (ABPA)

          4. Any oral, IV or inhaled antibiotics (except for macrolides) within 1 month prior to
             the start of the study

          5. Any IV or IM corticosteroids or change in oral corticosteroids (> 10 mg) within 1
             month prior to the start of the study

          6. Any change/start treatment regimens macrolides, hypertonic saline, inhaled mannitol or
             other mucolytics, corticosteroids within 1 month prior to the start of the study

          7. Change in physiotherapy technique or schedule within 1 month prior to the start of the
             study

          8. Severe immunosuppression or active malignancy

          9. Active tuberculosis

         10. Chronic renal insufficiency (eGFR < 30 ml/min), use of loop diuretics

         11. Have received an investigational drug or device within 1 month prior to the start of
             the study

         12. Serious or active medical or psychiatric illness

         13. Pregnancy and child bearing

         14. History of poor cooperation or non-compliance

         15. Unable to use nebulizers

         16. Allergic for tobramycin
"
NCT02661438,Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria

          -  Subjects (male and female) with non-cystic fibrosis bronchiectasis (NCFB) or chronic
             obstructive pulmonary disease (COPD)

          -  Subjects must be aged ≥40

          -  Subject must be able to independently manage and administer their NCFB/COPD
             medications

        Exclusion Criteria:

          -  Subjects with recent exacerbation

          -  Subjects with recent significant hemoptysis in the four weeks before screening (and/or
             during the screening period)

          -  Subjects allergic to quinine

          -  Known chronic bronchial asthma
"
NCT02712983,"Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Key Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Male and female patients of ≥ 18 years of age at screening (Visit 1).

          -  Proven diagnosis of non-CF BE as documented by computed tomography or high-resolution
             computed tomography

          -  At least 2 or more exacerbations treated with oral antibiotics OR 1 or more
             exacerbation requiring intravenous antibiotic treatment within 12 months prior to
             screening.

          -  FEV1 ≥ 30% predicted at screening (Visit 1).

          -  P. aeruginosa, must be documented in a respiratory sample at least 1 time within 12
             months and also present in the expectorated sputum culture at Visit 1.

        Key Exclusion Criteria:

          -  Patients with a history of cystic fibrosis.

          -  Patients with a primary diagnosis of bronchial asthma.

          -  Patients with a primary diagnosis of COPD associated with at least a 20 pack year
             smoking history.

          -  Any significant medical condition that is either recently diagnosed or was not stable
             during the last 3 months, other than pulmonary exacerbations, and that in the opinion
             of the investigator makes participation in the trial against the patients' best
             interests.

          -  Clinically significant (in the opinion of the investigator) hearing loss that
             interferes with patients' daily activities (such as normal conversations) or chronic
             tinnitus. Patients with a past history of clinically significant hearing loss in the
             opinion of the investigator may be eligible only if their hearing threshold at
             screening audiometry is 25dB or lower at frequencies 0.5-4 kHz. The use of a hearing
             device is reflective of a clinically significant hearing loss; hence patients using
             hearing aids at screening are not eligible.

          -  Patients with active pulmonary tuberculosis.

          -  Patients currently receiving treatment for nontuberculous mycobacterial (NTM)
             pulmonary disease.

          -  Patients who are regularly receiving inhaled anti-pseudomonal antibiotic (during the
             study inhaled anti-pseudomonal antibiotics are not allowed other than the study drug).
"
NCT02782312,Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  stable bronchiectasis; have the ability to complete the pulmonary function tests;
             FEV1/FVC<70%; ≥2 exacerbations within the past year

        Exclusion Criteria:

          -  a cigarette smoking history more than 10 pack-years;cystic fibrosis or traction
             bronchiectasis due to various pulmonary fibrosis; an active pulmonary mycobacterial
             infection; fungal infection; active sarcoidosis; active allergic bronchopulmonary
             aspergillosis (ABPA); asthma as defined by the Global Initiative for Asthma (GINA);
             patients with severe cardiopulmonary dysfunction; with impaired hepatic or kidney
             function; with hypogammaglobulinemia or other autoimmune diseases; pregnant or
             breast-feeding women; or patients with a known intolerance for ICS or LABAs.
"
NCT02823587,Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  clinically stable patients

          -  both sexes

          -  aged between 18-60 years

          -  not due to cystic fibrosis bronchiectasis diagnosis

          -  non smokers

          -  no pulmonary disease

        Exclusion Criteria:

          -  asthma or other restrictive conditions

          -  smokers assets

          -  decompensated cardiovascular and metabolic diseases, neuromuscular or musculoskeletal
             that impede the realization of the Protocol.
"
NCT02883101,The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Diagnosed bronchiectasis that is not attributable to cystic fibrosis, confirmed
             radiologically on high resolution computed tomography

          -  Exertional dyspnoea (Modified Medical Research Council (mMRC) score ≥ 2 and a history
             of at least two exacerbations in the past year

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Smoking history ≥ 10 pack years or physician diagnosis of chronic obstructive
             pulmonary disease

          -  A clinical diagnosis of asthma

          -  Interstitial lung disease (clinical/radiological diagnosis)

          -  Medical conditions which could place the individual at risk during exercise testing or
             training (eg. angina) or conditions that may restrict the participant's ability to
             exercise (eg. severe orthopaedic or neurologic impairments);

          -  Participation in a PR program within the last 12 months.

          -  Patient having an exacerbation of bronchiectasis
"
NCT03056326,"A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male subjects aged 18-55 years

          -  BMI between 18-30 kg/m2

          -  Non smokers

          -  Lung function above 80% of predicted normal value

          -  Healthy subjects based on medical evaluation including medical history, physical
             examination, laboratory tests and cardiac testing

        Exclusion Criteria:

          -  Any clinically relevant abnormalities and/or uncontrolled diseases

          -  Abnormal laboratory values

          -  Recent respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results

          -  Positive cotinine, alcohol, drug of abuse tests

          -  Unsuitable veins for repeated venepuncture
"
NCT03093974,Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. are able and willing to give informed consent, following a detailed explanation of
             participation in the protocol and signed consent obtained;

          2. aged 18 years or older of either gender;

          3. diagnosed with NCFB by computerised tomography (CT) or high resolution CT (HRCT) as
             recorded in the subject's notes and this is their predominant condition being treated;

          4. had at least 2 NCFB pulmonary exacerbations requiring oral or inhaled antibiotics or 1
             NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months
             preceding the Screening Visit (Visit 1) and had no NCFB pulmonary exacerbation with or
             without treatment during the period between Visit 1 and Visit 2;

          5. have a documented history of P. aeruginosa infection ;

          6. are clinically stable and have not required a change in pulmonary treatment for at
             least 30 days before the Screening Visit (Visit 1);

          7. have pre-bronchodilator FEV1 ≥25% of predicted;

          8. had a positive sputum culture for P. aeruginosa from an adequate sample taken at the
             Screening Visit (Visit 1) or during the screening period.

        Exclusion Criteria:

          1. known bronchiectasis as a consequence of cystic fibrosis (CF);

          2. known history of hypogammaglobulinaemia requiring treatment with immunoglobulin,
             unless fully replaced and considered immuno-competent by the Investigator;

          3. myasthenia gravis or porphyria;

          4. severe cardiovascular disease such as severe uncontrolled hypertension, ischaemic
             heart disease or cardiac arrhythmia and any other conditions that would confound the
             evaluation of safety, in the opinion of the Investigator;

          5. had major surgery in the 3 months prior to Screening Visit (Visit 1) or planned
             inpatient major surgery during the study period;

          6. receiving treatment for allergic bronchopulmonary aspergillosis (ABPA);

          7. had massive haemoptysis (greater than or equal to 300 mL or requiring blood
             transfusion) in the preceding 4 weeks before Screening Visit (Visit 1) or between
             Visit 1 and Visit 2;

          8. respiratory failure that would compromise patient safety or confound the evaluation of
             safety or efficacy of the study in the opinion of the Investigator;

          9. current active malignancy, except for basal cell carcinoma or squamous cell carcinoma
             of the skin without metastases;

         10. taking immunosuppressive medications (such as azathioprine, cyclosporine, tacrolimus,
             sirolimus, mycophenolate, rituximab), and/or anti-cytokine medications (such as anti
             IL-6 and anti-tumour alpha necrosis factor products) in the preceding year before the
             Screening Visit (Visit 1);

         11. known history of human immunodeficiency virus (HIV);

         12. current treatment for non-tuberculous mycobacterial (NTM) lung disease or
             tuberculosis;

         13. known or suspected to be allergic or unable to tolerate colistimethate sodium
             (intravenous or inhaled) or other polymixins, including previous evidence of bronchial
             hyperreactivity following inhaled colistimethate sodium;

         14. treatment with long term (≥ 30 days) prednisone at a dose greater than 15 mg a day (or
             equivalent dose of any other corticosteroid) within six months of the Screening Visit
             (Visit 1)

         15. new maintenance treatment with any oral macrolides (e.g.
             azithromycin/erythromycin/clarithromycin) started within 30 days of the Screening
             Visit (Visit 1) and between Visit 1 and Visit 2;

         16. use of any intravenous or intramuscular or oral or inhaled antipseudomonal antibiotic
             (except chronic oral macrolide treatment with a stable dose) within 30 days prior to
             Screening Visit (Visit 1) and between Visit 1 and Visit 2;

         17. pregnant or breast feeding or plan to become pregnant over the next year or of child
             bearing potential and unwilling to use a reliable method of contraception for at least
             one month before randomisation and throughout their involvement in the trial;

         18. significant abnormality in clinical evaluations and/or laboratory tests (physical
             examination, vital signs, haematology, clinical chemistry, clinically relevant
             impaired renal function, defined as serum creatinine levels ≥2.0x upper limit of
             normal, ECG) endangering the safe participation of the patient in the study at the
             Screening Visit (Visit 1) and during the study;

         19. participated in another investigational, interventional trial within 30 days prior to
             the Screening Visit (Visit 1);

         20. in the opinion of the Investigator not suitable for inclusion for whatever reason.
"
NCT03147651,Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Evidence of bronchiectasis on computed tomography (CT)

          -  Age > 7 years

          -  Height > 125cm

          -  Completed a maximal CPET test according to the accepted criteria

        Exclusion Criteria:

          -  Preforming submaximal CPET

          -  Lack of data from the exercise test

          -  Exacerbation of patient's condition within three days before the exercise evaluation

          -  Related chronic diseases affecting test results
"
NCT03218917,Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or
             recurrent respiratory infections)

          2. Are current sputum producers with a history of chronic expectoration and able to
             provide a sputum sample during Screening

          3. Have at least 2 documented pulmonary exacerbations in the past 12 months before
             Screening

        Exclusion Criteria:

          1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma

          2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common
             variable immunodeficiency, or alpha1-antitrypsin deficiency

          3. Are current smokers

          4. Are currently being treated for a nontuberculous mycobacterial lung infection,
             allergic bronchopulmonary aspergillosis, or tuberculosis

          5. Have any acute infections, (including respiratory infections)
"
NCT03428334,Roflumilast in Non-CF Bronchiectasis Study,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Aged 18 years or above, male or female.

          2. Never-smokers or those who have smoked less than 100 cigarettes in their lifetime.

          3. Confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed
             tomography (HRCT) scan.

          4. Significant sputum production (≥ 10 ml per day).

          5. In stable-state bronchiectasis with no change in regular medications (e.g. inhaled
             steroid, macrolide) or exacerbations in the past 3 months.

          6. Written informed consent obtained.

        Exclusion Criteria:

          1. Eversmokers (≥ 100 cigarettes in their lifetime).

          2. Known chronic obstructive pulmonary disease or asthma.

          3. Moderate to severe liver impairment (Child-Pugh B or C).

          4. Known psychiatric illness with increased suicidal risks.

          5. Body-mass index below 20 kg/m2.

          6. Concomitant use of strong cytochrome P450 inducers (e.g. rifampicin, phenobarbital,
             carbamazepine, phenytoin).

          7. Patients who are hypersensitive to roflumilast or its constituents.

          8. Pregnant or lactating women.
"
NCT03460704,Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II),TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. able and willing to give informed consent

          2. aged 18 years or older of either gender

          3. diagnosed with NCFB by computerised tomography (CT) or high-resolution CT(HRCT) as
             recorded in the subject's notes and this is their predominant condition being treated.

          4. had at least 2 NCFB pulmonary exacerbations requiring oral or inhaled antibiotics or 1
             NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months
             preceding the Screening Visit (V1) and had no pulmonary exacerbation with or without
             treatment during the period between Visit 1 and Visit 2

          5. have a documented history of P. aeruginosa infection;

          6. are clinically stable and have not required a change in pulmonary treatment for at
             least 30 days before the Screening Visit

          7. have pre-bronchodilator FEV1 ≥25% of predicted

          8. had a positive sputum culture for P. aeruginosa from an adequate sample taken at the
             Screening Visit or during the screening period.

        Exclusion Criteria:

          1. known bronchiectasis as a consequence of cystic fibrosis (CF)

          2. known history of hypogammaglobulinaemia requiring treatment with immunoglobulin,
             unless fully replaced and considered immuno-competent by the Investigator;

          3. myasthenia gravis or porphyria,

          4. severe cardiovascular disease such as severe uncontrolled hypertension, ischaemic
             heart disease or cardiac arrhythmia and any other conditions that would confound the
             evaluation of safety, in the opinion of the Investigator;

          5. had major surgery in the 3 months prior to the Screening Visit (Visit 1) or planned
             inpatient major surgery during the study period;

          6. receiving treatment for ABPA;

          7. massive haemoptysis (greater than or equal to 300 mL or requiring blood transfusion)
             in the preceding 4 weeks before Screening Visit (Visit 1) or between Visit 1 and Visit
             2;

          8. respiratory failure that would compromise patient safety or confound the evaluation of
             safety or efficacy of the study in the opinion of the Investigator;;

          9. current active malignancy, except for basal cell carcinoma or squamous cell carcinoma
             of the skin without metastases;

         10. taking immunosuppressive medications (such as azathioprine, cyclosporine, tacrolimus,
             sirolimus, mycophenolate, rituximab), and/or anti cytokine medications (such as
             anti-IL-6 and anti-tumour alpha necrosis factor products) in the preceding year before
             the Screening Visit (Visit 1);

         11. known history of human immunodeficiency virus (HIV);

         12. current treatment for non-tuberculous mycobacterial (NTM) lung disease or
             tuberculosis;

         13. known or suspected to be allergic or unable to tolerate colistimethate sodium
             (intravenous or inhaled) or other polymixins, including evidence of bronchial
             hyper-reactivity following inhaled colistimethate sodium;

         14. treatment with long term (≥ 30 days) prednisone at a dose of greater than 15 mg a day
             (or equivalent dose of any other corticosteroid) (e.g.
             azithromycin/erythromycin/clarithromycin) started within six months of the Screening
             Visit (Visit 1);

         15. new maintenance treatment with any oral macrolides within 30 days of the Screening
             Visit (Visit 1) or started between Visit 1 and Visit 2;

         16. use of any intravenous or intramuscular or oral or inhaled anti-pseudomonal antibiotic
             (except chronic macrolides with a stable dose) within 30 days prior to the Screening
             Visit (Visit 1) and between Visit 1 and Visit 2;

         17. pregnant or breast-feeding or plan to become pregnant over the next two years or of
             child-bearing potential and unwilling to use a reliable method of contraception for at
             least one month before randomisation and throughout their involvement in the trial;

         18. significant abnormality in clinical evaluations and/or laboratory tests (physical
             examination, vital signs, haematology, clinical chemistry, clinically relevant
             impaired renal function, defined as serum creatinine levels ≥2.0x upper limit of
             normal, ECG) endangering the safe participation of the patient in the study at the
             Screening Visit (Visit 1) and during the study;

         19. participated in another investigational, interventional trial within 30 days prior to
             the Screening Visit (Visit 1);

         20. in the opinion of the Investigator not suitable for inclusion for whatever reason.
"
NCT03818646,Functional Respiratory Imaging in Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Adult male and females ≥18 years and ≤ 80 years

          -  Current diagnosis of bronchiectasis (see above definition)

          -  Current pulmonary exacerbation (see above definition)

        Exclusion Criteria:

          -  Severe obstructive airways disease (defined as FEV1 < 30%; FEV1/FVC < 70%)

          -  Diagnosis of other active chronic lung disease (asthma; ABPA; COPD; pulmonary
             fibrosis)

          -  Currently treated non-tuberculous mycobacterial disease

          -  Acute congestive cardiac failure

          -  Contra-indication or unable to perform HRCT imaging, including pregnancy

          -  Contra-indication or unable to perform pulmonary function testing

          -  Active lung malignancy
"
NCT03988816,"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Age > 18 years;

          -  Diagnosis of bronchiectasis by chest tomography;

          -  FEV1 <60% of predicted;

          -  History of chronic bronchitis (chronic cough and sputum for at least 3 months in the
             last 2 years);

          -  2 or more infectious exacerbations in the last year (defined as worsening of cough and
             / or dyspnoea and / or decreased general condition, increased quantity and purulence
             of sputum that required systemic antibiotic use (oral or intravenous).

        Exclusion Criteria:

          -  Hemoptysis in the last 6 months (significance at the discretion of the investigator);

          -  Current or prior smoking if > 10 pack-years;

          -  FEV1 < 30% of predicted;

          -  Known allergy to roflumilast;

          -  Pulmonary exacerbation present or occurring in the last 4 weeks;

          -  Child B or C cirrhosis;

          -  Active cancer (except basal cell carcinoma);

          -  Severe heart failure;

          -  Depression associated with suicidal ideation;

          -  Pregnancy.
"
NCT04010799,"A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis",FALSE,Non-cystic Fibrosis Bronchiectasis,"
        INCLUSION CRITERIA:

        CF patients:

          -  Patient's written informed consent obtained prior to any study-related procedure;

          -  Male or female patient ≥ 18 years old with a confirmed historical diagnosis of cystic
             fibrosis;

          -  Ability to provide a spontaneous sputum sample at screening;

          -  Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before
             screening visit;

          -  Patient in stable clinical condition and free from exacerbation for at least 4 weeks
             prior to screening and/or prior to randomisation;

          -  Patient on stable concomitant treatment regimen within 4 weeks prior to screening
             and/or prior to randomisation;

          -  Patient with pre-bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or
             prior to randomisation;

          -  Vital signs within normal limits at screening and prior to randomisation;

        NCFB patients:

          -  Patient's written informed consent obtained prior to any study-related procedure;

          -  Male or female patient ≥ 18 years old with a diagnosis of Bronchiectasis confirmed by
             a historical Chest CT;

          -  Presence of clinically significant symptoms related to Bronchiectasis, such as daily
             cough that occurs over months or years, daily production of large amount of sputum,
             shortness of breath, wheezing chest pain;

          -  Ability to provide a spontaneous sputum sample at screening;

          -  Non- or ex-smokers who smoked < 10 pack years and stopped smoking > 1 year before
             screening visit;

          -  Patients in stable clinical condition and free from exacerbation since at least 4
             weeks before screening and/or prior to randomisation;

          -  Patients on stable concomitant treatment regimen within 4 weeks prior to screening
             and/or prior to randomisation

          -  Patient with pre- bronchodilator FEV1 ≥ 50% of predicted normal at screening and/or
             prior randomization visit;

          -  Vital signs within normal limits at screening and prior to randomisation

        EXCLUSION CRITERIA CF Patients

          -  Patient with BMI ≤ 17

          -  History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the
             opinion of the Investigator;

          -  Unstable pulmonary status or symptomatic respiratory tract infection and related
             changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks
             before screening or prior to randomisation;

          -  Abnormal and clinically significant 12-lead ECG at screening or prior to
             randomisation;

          -  History of asthma based on objective evidence;

          -  History of malignancy, solid organ/haematological transplantation;

          -  Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous
             Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;

          -  Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA)
             infection confirmed at screening or patient withABPA related bronchiectasis.

          -  Pregnant or lactating women.

          -  Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to
             screening or prior to randomization visit.

          -  Patient on cystic fibrosis transmembrane conductance regulator (CFTR) modulators and
             correctors if not on stable treatment regimen for at least 3 months prior to screening
             or prior to randomization.

          -  Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis
             serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening
             (i.e. positive HB surface antigen (HBsAg), HB core antibody (anti-HBc), HC antibody);

        NCFB Patients

          -  Patient with BMI ≤ 17

          -  History of a clinically meaningful unstable or uncontrolled chronic comorbidity in the
             opinion of the Investigator;

          -  Unstable pulmonary status or symptomatic respiratory tract infection and related
             changes in therapy for pulmonary disease as per Investigator's judgment within 4 weeks
             before screening or prior to randomisation.

          -  Abnormal and clinically significant 12-lead ECG at screening or prior to randomisation
             that results in active medical problem which may impact the safety of the patients as
             per Investigator's judgment.

          -  History of malignancy, solid organ/haematological transplantation;

          -  Known diagnosis of cystic fibrosis. A negative sweat test is required at screening
             (sweat chloride should be < 40 mmol/L);

          -  History of asthma based on objective evidence of the condition;

          -  Patient with primary diagnosis of COPD in the opinion of theInvestigator;

          -  Patient with rheumatoid factor positivity;

          -  Patient with evidence of active Nontuberculous Mycobacteria (NTM) and Tuberculous
             Mycobacteria (TM) infection or related bronchiectasis in the past 12 months;

          -  Patient with a positive test for active Allergic Bronchopulmonary Aspergillosis (ABPA)
             infection confirmed at screening or patient with ABPA related bronchiectasis;

          -  Patient with Connective Tissue Disease (CTD) related bronchiectasis;

          -  Diagnosis of common variable immunodeficiency (CVID);

          -  Patient on any antibiotics (except for stable macrolides treatment),oral, inhaled and
             IV, within 4 weeks prior to screening or prior to randomisation;

          -  Patient on oral corticosteroids within 4 weeks prior to screening visit or prior to
             randomization.

          -  Patient on non-steroidal anti-inflammatory drugs (NSAIDs) within 4 weeks prior to
             screening or randomization visit.

          -  Patient on Carbocysteine and Mannitol treatment within 4 weeks before the screening or
             randomization visit.

          -  Patient with traction bronchiectasis;

          -  Patient with any condition that prevent them to use inhaledantibiotics (including
             patients who previously experienced adverse reaction to inhaled antibiotics;

          -  Patient treated with monoclonal antibodies (mAb);

          -  Pregnant or lactating women.

          -  Positive HIV1 or HIV2 serology at screening; Positive results from the Hepatitis
             serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening
             (i.e. positive HB surface antigen (HBsAg), HBcore antibody (anti-HBc), HC antibody).
"
NCT04017312,A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Radiological diagnosis of Bronchiectasis based on high resolution chest CT scan

          -  History of at least 2 acute exacerbations or hospitalizations in the past 12 months

          -  Clinically stable for >2 weeks prior to study entry

          -  FEV1 >30% predicted

          -  Age18-80 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Diagnosis of Cystic Fibrosis

          -  History of bronchiectasis secondary to primary immunodeficiency

          -  Active pulmonary tuberculosis

          -  Active treatment of Non-Tuberculous Mycobacterium (NTM)

          -  Patients currently on HFCWO treatment

          -  Diagnosed comorbidity or medical indication that would prevent study completion

          -  History of pneumothorax within past 6 months

          -  History of hemoptysis requiring embolization within past 12 months

          -  Inability to perform HFCWO therapy or OPEP therapy as directed

          -  Pregnancy or lactation

          -  Inability or unwillingness to complete study visits or provide follow-up data as
             required by the study protocol
"
NCT04090294,Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Aged 18 years or above, male or female.

          -  Non / Ex-smokers.

          -  Confirmed diagnosis of bronchiectasis based on high-resolution computed tomography
             scan.

          -  Significant sputum production (≥ 10 ml per day).

        Exclusion Criteria:

          -  Non-stable patients who need ICU admission /mechanical ventilation.

          -  Active smokers.

          -  Moderate to severe liver impairment (Child-Pugh B or C) and/or sever renal impairment
             (c. clearance less than 30ml/min).

          -  Known psychiatric illness

          -  Concomitant use of strong cytochrome P450 inducers (e.g. rifampicin)

          -  Patients who are hypersensitive to roflumilast.

          -  Pregnant or lactating women
"
NCT04122547,Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  symptomatic Bronchiectasis

          -  history at least 2 exacerbation last year

        Exclusion Criteria:

          -  comorbidity with chronic obstructive pulmonary disease
"
NCT04170114,Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Being between 6-18 years old

          -  Clinically diagnosed as cystic fibrosis or non-cystic fibrosis bronchiectasis

        Exclusion Criteria:

          -  Previous history of lung or liver transplantation

          -  Have had an acute exacerbation in the last month and / or have a history of
             hospitalization

          -  Having a diagnosis of orthopedic problems affecting mobility or a history of
             musculoskelatal surgery
"
NCT04278040,Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Signed informed consent form

          -  Established diagnosis witn CT scan of non-cystic fibrosis bronchiectasis more than 12
             months before the screening visit.

          -  Sputum expectoration not less than 3 months per year during more than 2 consecutive
             years

          -  Willing of the patient for cooperation

        Non-Inclusion Criteria:

          -  Pregnant and lactating women and all women who are physiologically capable of becoming
             pregnant, who do not agree to use one or more of the following effective methods of
             contraception: intrauterine device or intrauterine system; hormonal contraception
             (implantable and oral preparations, patches); barrier methods of contraception; male
             sterilization (with appropriate documentation after a vasectomy about the absence of
             sperm in the ejaculate).

        Effective contraception is used throughout the study until the last visit. ""True
        abstinence"" is acceptable only if it corresponds to the patient's preferred and habitual
        way of life.

        Postmenopausal women (physiological menopause is defined as ""no menstruation for 12
        consecutive months"") and women who have undergone sterilization surgery (for example, tubal
        occlusion, hysterectomy or bilateral salpingectomy) can be included in the study.

          -  A history of cystic fibrosis.

          -  Any exacerbation of respiratory infection requiring the use of systemic
             corticosteroids and / or antibiotics or hospitalization, which developed after the
             signing of the informed consent form and before the randomization visit (day 1, start
             of treatment). The criterion should be specified during the randomization visit.

          -  The presence of hemoptysis at the time of inclusion in the study.

          -  The presence of diseases of the respiratory tract, in addition to bronchiectasis,
             which can affect the effectiveness of the study drug and patient safety. Such
             conditions may include, among others, active tuberculosis, lung cancer, sarcoidosis,
             chronic obstructive pulmonary disease (COPD) IV (GOLD, 2017), uncontrolled bronchial
             asthma with respiratory failure, high pulmonary hypertension (> 25 mm Hg),
             interstitial lung disease, etc.

          -  Patients with a clinical significant disease of the cardiovascular system (for
             example, unstable angina, chronic heart failure New York Heart Association (NYHA) III
             / IV, acute myocardial infarction (within 6 months before inhalation of 1 dose), etc.

          -  Atrial fibrillation patients.

          -  Clinical significant 12-lead ECG abnormalities that may affect patient safety. The
             corrected QT interval (QTc) interval on the electrocardiogram (ECG in 12 leads) is
             more than 450 ms for men and more than 470 ms for women on screening and randomization
             visits.

          -  A history of hypersensitivity to any of the substances used in the study.

          -  Clinically significant deviations of laboratory parameters, indicating a significant
             or unstable concomitant disease, which may affect the effectiveness of the study drug
             or patient safety.

          -  Hemostasis deviation within 1 month before the first inhalation of the study drug,
             including confirmed:

               -  Hemoglobin <10 g / 100 ml;

               -  White blood cell count <3.0 x 10*9 / L;

               -  The absolute number of neutrophils ≤ 1.5 x 10*9 / L;

               -  Platelet count <100 x 10*9 / L.

          -  Unstable concomitant disease, such as uncontrolled hyperthyroidism, uncontrolled
             diabetes or other endocrine diseases; significant impairment of liver and kidney
             function; uncontrolled gastrointestinal diseases (for example, active peptic ulcer);
             uncontrolled neurological diseases; uncontrolled hematological diseases; uncontrolled
             autoimmune diseases or other diseases that, according to the researcher, may affect
             the effectiveness of the study drug and patient safety.

          -  Alcohol and/or drugs abuse 12 months before screening visit.

          -  Failure to perform tests to evaluate external respiration function, perform research
             procedures, or adhere to the treatment schedule provided for in the study.

          -  Participation in another clinical trial in which the study drug was administered less
             than 8 weeks before the screening visit.

        Exclusion criteria:

          -  Informed consent withdrawn by the patient.

          -  The patient doesn't follow the instructions of the research staff regarding the
             requirements of the research protocol.

          -  Unable to contact patient.

          -  The researcher believes that participation in the study is not in the interests of the
             patient and / or further participation in the study is unsafe for the patient's
             health.

          -  There is a violation of the criteria for inclusion and / or non-inclusion in the
             study.

          -  The patient has developed adverse event, which, according to the researcher, makes
             further participation in the study unsafe for the patient.

          -  The licensing authority or ethics committee, for any reason, decides to discontinue
             the entire study or close this research center.

          -  A female patient becomes pregnant, is planning a pregnancy, or is breastfeeding while
             participating in this study.
"
NCT04322929,Roflumilast in Non-CF Bronchiectasis Study (2019),FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Aged 18 years or above, male or female.

          2. Never-smokers or those who have smoked less than 100 cigarettes in their lifetime.

          3. Confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed
             tomography (HRCT) scan.

          4. Significant sputum production (≥ 10 ml per day).

          5. In stable-state bronchiectasis with no change in regular medications (e.g. inhaled
             steroid, macrolide) or exacerbations in the past 3 months.

          6. Written informed consent obtained.

        Exclusion Criteria:

          1. Eversmokers (≥ 100 cigarettes in their lifetime).

          2. Known chronic obstructive pulmonary disease or asthma.

          3. Moderate to severe liver impairment (Child-Pugh B or C).

          4. Known psychiatric illness with increased suicidal risks.

          5. Body-mass index below 18 kg/m2.

          6. Concomitant use of strong cytochrome P450 inducers (e.g. rifampicin, phenobarbital,
             carbamazepine, phenytoin).

          7. Patients who are hypersensitive to roflumilast or its constituents.

          8. Pregnant or lactating women.
"
NCT04509661,Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Idiopathic bronchiectasis with FEV1/FVC < 70%

        Exclusion Criteria:

          -  With Asthma

          -  α-1 antitrypsin deficiency

          -  Turculosis

          -  Lung cancer

          -  Sarcoidosis

          -  Idiopathic pulmonary fibrosis

          -  Primary pulmonary hypertension

          -  Uncontrolled sleep apnea

          -  Bronchiectasis accepted long-term low dose macrolides

          -  Pulmonary surgery within 6 months

          -  Lower respiratory tract infections require antibiotic treatment in 6 weeks

          -  Upper respiratory tract infection did not recover for at least 7 days

          -  With Glaucoma or severe prostate hyperplasia that can not use Indacaterol

          -  Patients allergic to experimental drugs

          -  Women pregnant, breast-feeding or who planned a pregnancy during the study
"
NCT04538859,A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Patients aged 18 years or older

          2. Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of
             exacerbation, no requirement for supplemental antibiotic therapy)

          3. Diagnosis of bronchiectasis defined by high-resolution computed tomography scan

        Exclusion Criteria:

          1. History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary
             aspergilosis

          2. Those who are unable to give consent
"
NCT04594369,"A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis",TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          1. Provide their signed study informed consent to participate.

             a. Adolescent participants must have signed study assent form to participate, and the
             adolescent's parent or legal guardian must have provided signed informed consent for
             the adolescent to participate.

          2. Clinical history consistent with non-cystic fibrosis bronchiectasis (NCFBE) (cough,
             chronic sputum production and/or recurrent respiratory infections) that is confirmed
             by chest computerized tomography (CT) scan.

          3. At least 2 PEs defined by need for antibiotic prescription by a physician for the
             signs and symptoms of respiratory infections in the past 12 months before the
             Screening Visit.

             a. Adolescent participants are required to have at least 1 pulmonary exacerbation in
             the prior 12 months.

          4. Women must be postmenopausal (defined as no menses for 12 months without an
             alternative medical cause), surgically sterile, or using highly effective
             contraception (ie, methods that can achieve a failure rate <1% per year when used
             consistently and correctly) from Day 1 to at least 90 days after the last dose.

          5. Male participants with female partners of childbearing potential must be using
             effective contraception from Day 1 to at least 90 days after the last dose.

          6. Male participants with pregnant or non-pregnant women of child-bearing potential
             partners must use condoms to avoid potential exposure to the embryo/fetus.

        Exclusion Criteria:

          1. A primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma as
             judged by the Investigator.

          2. Bronchiectasis due to cystic fibrosis.

          3. Current smokers as defined per Centers for Disease Control (CDC).

          4. Known or suspected immunodeficiency disorder, including history of invasive
             opportunistic infections.

          5. Known history of human immunodeficiency virus (HIV) infection.

          6. Currently being treated for nontuberculous mycobacteria (NTM) lung infection, allergic
             bronchopulmonary aspergillosis, or tuberculosis (TB).

          7. Active and current symptomatic infection by COVID-19.

          8. Inability to follow the procedures of the study (eg, due to language problems or
             psychological disorders).

          9. Receiving medications or therapy that are prohibited as concomitant medications.

         10. Previously participated in a clinical trial for brensocatib.

         11. Received any live attenuated vaccine within 4 weeks prior to the first administration
             of brensocatib.

         12. Suffering an exacerbation 4 weeks before Screening or during the Screening period.

         13. Adult participants only: Have compliance issues with completion of electronic diary
             entries during the Screening Period and in the opinion of the Investigator, compliance
             is unlikely to improve during the study.

         14. Participated in any other interventional clinical studies within 3 months before
             Screening Visit.

         15. History of alcohol or drug abuse within 6 months prior to the Screening Visit.

         16. Is the Investigator or any Sub-Investigator, research assistant, pharmacist, study
             coordinator, other staff or relative thereof directly involved in the conduct of the
             study.

         17. Known history of hypersensitivity to brensocatib or any of its excipients.
"
NCT04643587,Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB),FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male or female, aged ≥ 18 years at the time of providing written informed consent

        For Part A (SAD) Only:

          -  Healthy and free of medical conditions that could in the opinion of the investigator
             affect's the subject's participation in the study or the interpretation of results.

        For Part B (MAD) Only:

          -  Diagnosis of NCFB made by a respiratory physician, confirmed per CT showing bronchial
             wall dilatation with or without bronchial wall thickening, with a FEV1 ≥ 65% of the
             predicted value regarding age, height, gender, ethnicity, and FEV1 ≥ 1.5 L at the
             Screening Visit.

          -  No antibiotic use for respiratory infection within last 3 months before the Screening
             Visit.

          -  Presence of one or more of the following bacteria (H. influenzae, P. aeruginosa, M.
             catarrhalis, S. pneumoniae, members of Enterobacterales family or S. aureus) in the
             sputum culture at the Screening Visit.

          -  Has been fully vaccinated against COVID-19 (as per country recommendations) at least 7
             days prior to Day 1

        Exclusion Criteria:

          -  Evidence of a clinically significant medical condition, disorder, or disease,
             including but not limited to any of the following: hepatic (hepatitis, cirrhosis);
             biliary; renal; cardiac; bronchopulmonary; vascular; hematologic; gastrointestinal;
             allergy; endocrine / metabolic (diabetes, thyroid disorders, adrenal disease);
             neurologic; psychiatric; immunodeficiency; cancer.

          -  History of chronic respiratory disease (eg, COPD or bronchiectasis) or current asthma
             with regular treatment including occasional use of an inhaler for exercise induced
             asthma.

          -  Current moderate-severe allergic disease (eg, allergic rhinitis) with regular
             treatment.

          -  Diagnosis of cystic fibrosis, mycobacterial disease, connective tissue disease,
             alpha-1 antitrypsin deficiency or asthma as underlying disease for bronchiectasis.

          -  Inhaled therapy or oral corticosteroid 28 days before the Screening Visit until EOS
             Visit. Use of long acting bronchodilators (long acting muscarinic antagonists (LAMA)
             and / or long acting beta2 agonists (LABA) that have been at a stable dose for at
             least 3 months before the Screening Visit is permitted; inhalation with hypertonic
             saline solution is permitted up to and including Day -1.

          -  Any systemic antibiotic for acute exacerbation within 3 months before the Screening
             Visit until EOS Visit.
"
NCT04656275,A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  18 years to 80 years (inclusive) at the time of informed consent signature, male and
             female (not of childbearing potential) subjects

             --For 'female not of childbearing potential' at least one of the following criteria
             must be fulfilled:

               -  Permanently sterile (permanent sterilisation methods include hysterectomy,
                  bilateral salpingectomy, and bilateral oophorectomy; tubal ligation is not a
                  method of permanent sterilisation)

               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea without an
                  alternative medical cause (in questionable cases a blood sample with Follicle
                  Stimulating Hormone (FSH) above 40 U/L and estradiol below 30 ng/L is
                  confirmatory).

               -  Men must be vasectomised with documented absence of sperm or use male
                  contraception (condom or sexual abstinence) from the first administration of
                  trial medication until 30 days after the last administration of trial medication
                  if their sexual partner is a woman of childbearing potential (WOCBP)

          -  Clinical history consistent with non cystic fibrosis bronchiectasis (nCFB) (cough,
             chronic sputum production and/or recurrent respiratory infections) and proven and
             documented diagnosis of bronchiectasis by computed tomography (CT) scan including
             dilated airways compatible with bronchiectasis at initial diagnosis. Bronchiectasis of
             various etiologies will be allowed, with exclusion criteria as below.

          -  Vaccination against Streptococcus pneumoniae in accordance with national vaccination
             recommendations

          -  Signed and dated written informed consent prior to admission to the study, in
             accordance with Good Clinical Practice (GCP) and local legislation.

          -  FEV1 ≥ 30 % predicted (post-bronchodilator) at Screening Visit 1.

          -  Stable (i.e., no dose change) regimen of standard nCFB treatment (including - but not
             limited to - hypertonic inhalation solutions, mucolytics, Long Acting Muscarinic
             Agonists (LAMA)/ Long Acting Beta Agonists (LABA) / inhaled corticosteriods (iCS),
             oral antibiotic maintenance regimen, and physiotherapy), if applicable, administered
             at least for 4 weeks prior to Screening Visit 1 and throughout the run-in period.

          -  Regular daily sputum producers with a history of chronic expectoration who are able to
             provide a typical bronchiectasis sputum sample at Screening Visit 1.

          -  Sputum neutrophil elastase positive based on point of care test (NEATstik® score ≥ 6)
             assessment at Visit 2a and Visit 2b.

          -  Subjects genotyped as UDP-Glucuronosyltransferase-2B17 (UGT2B17) extensive
             metabolizers prior to randomisation, i.e., carrying at least one functional allele of
             the UGT2B17 gene (*1/*1 or *1/*2)

        Exclusion Criteria:

          -  Any finding in the medical examination (including BP, pulse rate (PR), or ECG) and/or
             laboratory value and/or any evidence of a concomitant disease assessed as clinically
             relevant by the investigator.

          -  Concomitant diagnosis of pulmonary disease other than bronchiectasis, chronic
             obstructive pulmonary disease (COPD), or asthma.

          -  A current diagnosis of cystic fibrosis (CF), primary immunodeficiency, active Allergic
             Bronchopulmonary Aspergillosis (ABPA) (defined by receipt of corticosteroids,
             anti-fungal treatment or monoclonal antibody treatment), or alpha-1 antitrypsin (A1AT)
             deficiency as underlying disease.

          -  A history or current immunodeficiency or are currently being treated (or are planned
             to be treated) with immunomodulatory drugs (except for iCS or low-dose oral
             corticosteroids), including disease-modifying anti-rheumatic drugs (DMARDs), and/or
             Immunglobulin G (IgG) treatments. Other medication that is excluded will be provided
             in the investigator site file (ISF). On the day of the site visit with lung function
             measurement, no bronchodilators should be used until after completion of lung function
             assessment

          -  Any acute infections defined as infections requiring antibiotic therapy, or Upper
             Respiratory Tract Infection (URTI). Are currently being treated (or are planned to be
             treated) for a nontuberculous mycobacterial (NTM) lung infection or tuberculosis.

          -  A history of invasive pneumococcal disease.

          -  Inhaled antibiotic treatment or cycling oral antibiotic treatment with changed dose
             regimen 4 weeks prior to Screening Visit 1.

          -  A treatment for a pulmonary exacerbation 4 weeks prior to Screening Visit 1.

          -  Laboratory confirmed severe acute respiratory syndrome (SARS)-coronavisurs (CoV)-2
             infection (PCR positive) within 4 weeks prior to Screening Visit 1.

          -  Household contact with an individual with confirmed SARS-CoV-2 infection within 4
             weeks prior to Screening Visit 1.

          -  Further exclusion criteria apply
"
NCT04658277,Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Patients aged 50 years or older

          -  At least 2 or more exacerbation requiring antibiotic treatment in the past year
             Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of
             exacerbation, no requirement for supplemental antibiotic therapy)

          -  Diagnosis of bronchiectasis defined by high-resolution computed tomography (CT) scan

        Exclusion Criteria:

          -  History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary
             aspergilosis,

          -  Cigarette smoking within 6 months

          -  A positive culture of non-tuberculosis mycobacteria in the past 2 years or at
             screening

          -  Macrolide treatment for more than 3 months in the past 6 months

          -  Oral or intravenous courses of corticosteroids within 30 days of screening

          -  Any antimicrobial treatment for lower respiratory tract infection in the last 2 weeks

          -  Unstable arrhythmia

          -  History of coronary artery disease, or symptoms of heart disease

          -  Known allergy or intolerance to macrolides

          -  Patients with liver disease or with elevated transaminanse (aspartate aminotransferase
             (AST) and alanine aminotransferase (ALT) levels equal to or greater than the upper
             limit of the normal)

          -  Concurrent medication: Colchicine, calcium channel blocker, statins, amiodarone,
             amitriptyline, trazodone, citalopram, disopyramide, itraconazole, saquinavir,
             ritaonavir, atazanavir, sildenafil, tadalafil, vardenafil, theophylline,
             carbamazepine.
"
NCT04884308,Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria (CF and non-CF bronchiectasis):

          -  Confirmed diagnosis of either CF or non-CF bronchiectasis

          -  Forced expiratory volume over one second (FEV1) > 40%

          -  Willingness to participate in the study after all aspects of the protocol have been
             explained and written informed consent obtained.

          -  Available for the study duration, including all planned follow-up visits

        Inclusion Criteria (Healthy Volunteers):

          -  Negative HIV enzyme-linked immunosorbent assay (ELISA) and confirmatory test at
             screening.

          -  Willingness to participate in the study after all aspects of the protocol have been
             explained and written informed obtained.

          -  Available for the study duration, including all planned follow-up visits

        Exclusion Criteria (All arms):

          -  Current or prior history of active or latent tuberculosis (TB) (per report, not
             formally tested) or NTM infection

          -  Prior BCG vaccination

          -  Previous vaccine in the past 4 weeks

          -  History of severe anaphylaxis to any vaccine or vaccine components

          -  History of organ/bone marrow transplantation or other immunosuppressing condition,
             including HIV

          -  Immunosuppressing drugs (including oral corticosteroids equivalent to >10mg of
             prednisone for 5 days) in the 30 days prior to study enrollment

          -  Cirrhosis or portal hypertension

          -  Pregnant or breastfeeding

          -  Receipt of another investigational product in the last 28 days or planned receipt
             during this study

          -  Has any other condition that, in the opinion of the principal investigator, would
             preclude informed consent, make study participation unsafe, complicate interpretation
             of study outcome data, or otherwise interfere with achieving study objectives.
"
NCT05006573,Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis,TRUE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Male or female, at least 18 years of age inclusive at the time of signing the ICF

          -  Must have NCFB diagnosed by a physician and confirmed by CT (measured at screening; if
             a new CT is not possible, a CT performed within 12 months of the screening visit is
             acceptable).

          -  Documented history of 2 or more bronchiectasis exacerbations within a year of the
             screening visit.

          -  If receiving prophylactic systemic or inhaled antibiotics to prevent bronchiectasis
             exacerbations, the dose/regimen must be stable for at least 3 months prior to the
             screening visit and remain stable throughout the DB period of the study. If
             prophylactic macrolides have been recently discontinued, patients must have been off
             treatment for at least 3 months prior to randomisation. In all other cases of
             prophylactic antibiotic use, ≥ 4 weeks wash out period should be in place after the
             last dose of antibiotic and prior to randomisation

          -  Must be on airway clearance therapy, physiotherapy, or mucus clearance therapy.The
             dose and regimen of these therapies and any drugs used to aid expectoration should be
             stable for at least 3 months prior to the screening visit and remain stable throughout
             the DB period of the study.

          -  If receiving inhaled corticosteroid or bronchodilator therapy, the dose and regimen
             should be stable with no alteration to dose or formulation for at least 3 months prior
             to the screening visit and this should remain stable throughout the DB period of the
             study.

          -  Women of childbearing potential (WOCBP) must have a negative serum and urine pregnancy
             test prior to randomization and agree to use a highly effective method of birth
             control from enrollment, throughout the study duration, and for 12 weeks after the
             last dose of IP.

        Exclusion Criteria:

          -  Pulmonary disease other than bronchiectasis. Patients with a history of NTM disease
             may be enrolled if they have completed treatment prior to the Screening visit, if at
             least 3 months have elapsed since the last day of antibiotic treatment for NTM at the
             Screening visit, and if they have had a negative sputum culture prior to the screening
             visit.

          -  Another diagnosed or suspected pulmonary or systemic disease associated with elevated
             peripheral eosinophil counts

          -  Respiratory infection or bronchiectasis exacerbation during the screening period.

          -  Any other clinical condition that is not stable in the opinion of the Investigator and
             could:

               1. Affect the safety of the patient during the study.

               2. Influence the findings of the study or their interpretation.

               3. Impede the patient's ability to complete the entire duration of the study.

          -  Radiological findings suggestive of a respiratory disease other than bronchiectasis,
             suggestive of acute infection, or of solitary pulmonary nodules without appropriate
             follow up and demonstration of stability as per standard of care. Pulmonary nodules >
             6 mm in size should have at least 2 years of follow up with no change on CT imaging.

          -  Current active liver disease

          -  Current malignancy, or history of malignancy, except for:

               1. Patients who have had basal cell carcinoma, localised squamous cell carcinoma of
                  the skin, or in situ carcinoma of the cervix are eligible provided the patient is
                  in remission and curative therapy was completed at least 12 months prior to Visit
                  1

               2. Patients who have had other malignancies are eligible provided that the
                  participant is in remission and curative therapy was completed at least 5 years
                  prior to Visit 1.

          -  History of known immunodeficiency disorder including a positive test for human
             immunodeficiency virus, HIV-1 or HIV-2.

          -  History of alcohol or drug abuse within the past year

          -  Current smokers with a tobacco history of ≥ 10 pack-years or ex-smoker with a tobacco
             history of ≥ 10 pack-years.

          -  Patients receiving long-term oxygen treatment

          -  Patients participating in, or scheduled for, an intensive (active) pulmonary
             rehabilitation programme. Patients who are in the maintenance phase of a
             rehabilitation programme are eligible.

          -  Use of non-invasive positive-pressure ventilation for conditions other than
             obstructive sleep apnoea

          -  Use of immunosuppressive medication within 3 months of the screening visit or expected
             need for chronic use (≥ 4 weeks) during study

          -  Receipt of any marketed or investigational biologic products (monoclonal or polyclonal
             antibody) within one year of the screening visit

          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives
             prior to randomisation

          -  Receipt of immunoglobulin and blood products within 30 days of the date of the
             screening visit

          -  Receipt of live attenuated vaccines within 30 days of the date of randomisation

          -  Concurrent enrolment in another clinical drug interventional trial

          -  History of anaphylaxis to any biologic therapy or vaccine

          -  Known history of allergy or reaction to any component of the IP formulation.

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          -  Judgement by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions, and
             requirements

          -  Previous randomisation in the present study

          -  Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
"
NCT05344508,An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Participant had agreed to provide their informed consent to participate per local
             requirements.

          -  Participant had successfully completed Clinical Trial INS 1007-301 ASPEN, including
             the End of study Visit 12 prior to receiving treatment.

          -  Requests for Post-Trial access for brensocatib had come from ASPEN investigator.

          -  Had received brensocatib treatment.

        Exclusion Criteria:

          -  Participant had experienced a serious adverse event deemed to be related to
             brensocatib during the study and required permanent participant is continuation.

          -  The participant is immunocompromised or chronically treated with any investigational
             or commercialized immunomodulatory agent that is directed to any component of the
             adaptive or innate immune systems.

        Note: The use of any immunomodulatory agents (including but not limited to: bortezomib,
        ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-γ, and
        azathioprine) is prohibited during the program.

          -  The participant had undergone continuous use of high dose non-steroidal
             anti-inflammatory drugs.

          -  The participant had undergone chronic use of systemic steroids for any chronic
             condition, except steroids with topical anti-inflammatory activities (ie, oral
             budesonide).

          -  Participant had planned to receive live attenuated vaccines during the program
             (treatment must be postponed until 4 weeks after the last dose of drug).

          -  Participant had planned to use investigational drugs.
"
NCT05369624,Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program,FALSE,Non-cystic Fibrosis Bronchiectasis,"
        Inclusion Criteria:

          -  Certain diagnosis of non-CF bronchiectasis (chest HRCT)

          -  Over 18 years old, clinically stable in the previous 6 weeks (no need for antibiotic
             therapy due to exacerbations) and a dyspnea score over 1 according to the modified
             Medical Research Council (mMRC) dyspnea scale

        Exclusion Criteria:

          -  Less of 18 years

          -  Other airway disease ( Asthma or COPD)

          -  Physical inability to perform a physical training program (neuromuscular pathology or
             residual injuries).

          -  Smokers or former smokers of less than 6 months or with a history of consumption of 15
             packs/year.

          -  Cystic fibrosis.

          -  Active infections (bronchopulmonary aspergillosis, pulmonary tuberculosis).

          -  Active tuberculosis.

          -  Medical illnesses that put the individual at risk of a decompensation due to the
             performance of any physical activity or cardiopulmonary stress test (unstable ischemic
             heart disease, acute myocardial infarction less than 1 month).

          -  Pregnancy

          -  Mental disorder that prevents the adequate interpretation of the indications or
             performance of the tests.

          -  Attended pulmonary rehabilitation within 1 year.
"
